Presympto's unique scientific applications - based on the role of protein misfolding conformation in certain diseases - fuel a discovery engine with the power to unlock the potential for next-generation diagnostics.
We used spectroscopic techniques to establish specific detection of Aβ oligomers with our peptides. We measured the binding capacity index (BCI) of Red Blood Cells (RBC) using the following assay: diluted whole blood was incubated with or without our proprietary stabilized Aβ oligomer; Pronucleon™ peptide was incubated with the blood samples followed by flow cytometric analysis. We compared the RBC fluorescence intensity of each sample, one with and one without the stabilized Aβ oligomer. We performed the RBC flow cytometry assay on human AD clinical samples provided by AD clinics and compared them with healthy controls.